Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 48 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2014', provides an overview of the Microscopic Polyangiitis (MPA)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Microscopic Polyangiitis (MPA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Microscopic Polyangiitis (MPA) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Microscopic Polyangiitis (MPA) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Microscopic Polyangiitis (MPA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Microscopic Polyangiitis (MPA) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Microscopic Polyangiitis (MPA)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Microscopic Polyangiitis (MPA) Overview 6
Therapeutics Development 7
Pipeline Products for Microscopic Polyangiitis (MPA) - Overview 7
Pipeline Products for Microscopic Polyangiitis (MPA) - Comparative Analysis 8
Microscopic Polyangiitis (MPA) - Therapeutics under Development by Companies 9
Microscopic Polyangiitis (MPA) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Microscopic Polyangiitis (MPA) - Products under Development by Companies 13
Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development 14
Anthera Pharmaceuticals� Inc. 14
Aprogen, Inc. 15
ChemoCentryx, Inc. 16
Epirus Biopharmaceuticals, Inc. 17
Panacea Biotec Limited 18
Sandoz Inc. 19
Microscopic Polyangiitis (MPA) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
blisibimod - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CCX-168 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
rituximab biosimilar - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
rituximab biosimilar - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
rituximab biosimilar - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
rituximab biosimilar - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
rituximab biosimilar - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Microscopic Polyangiitis (MPA) - Recent Pipeline Updates 39
Microscopic Polyangiitis (MPA) - Dormant Projects 45
Microscopic Polyangiitis (MPA) - Product Development Milestones 46
Featured News & Press Releases 46
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Number of Products under Development for Microscopic Polyangiitis (MPA), H2 2014 7
Number of Products under Development for Microscopic Polyangiitis (MPA) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Microscopic Polyangiitis (MPA) - Pipeline by Anthera Pharmaceuticals� Inc., H2 2014 14
Microscopic Polyangiitis (MPA) - Pipeline by Aprogen, Inc., H2 2014 15
Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx, Inc., H2 2014 16
Microscopic Polyangiitis (MPA) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 17
Microscopic Polyangiitis (MPA) - Pipeline by Panacea Biotec Limited, H2 2014 18
Microscopic Polyangiitis (MPA) - Pipeline by Sandoz Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Microscopic Polyangiitis (MPA) Therapeutics - Recent Pipeline Updates, H2 2014 39
Microscopic Polyangiitis (MPA) - Dormant Projects, H2 2014 45